Stepwise Heat-Denaturated Protein Introduction for Tolerance Induction in Food Allergy

NCT ID: NCT06380673

Last Updated: 2024-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-22

Study Completion Date

2029-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This interventional study aims to validate an early heated protein introduction protocol in cow's milk allergic children who already developed tolerance towards extensively heated cow's milk, in order to speed up the development of complete cow's milk tolerance. Natural complete tolerance induction towards cow's milk takes several years of strict cow's milk avoidance with high risk of anaphylaxis by accidental cow's milk intake. By shortening the time towards complete tolerance, not only the quality of life of both children and parents ameliorates drastically, the time frame for potential anaphylactic reactions is also strongly reduced and can be considered as a preventive strategy to reduce allergic reactions too. Moreover, this strategy has proved efficient for hen's egg allergy. The main question this study wants to answer is whether a 12 months stepwise heated cow's milk introduction (either by gradual reduction of the cooking time or by the use of the Flemish Milk Ladder) in 20'-cooked cow's milk tolerant subjects, results in a larger proportion of complete cow's milk tolerant children after 12 months compared to natural tolerance induction (with 20' cooked milk introduction only).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

WP 1: Gradual introduction of less heated cow's milk proteins in 20'-cooked cow's milk tolerant children.

When inclusion criteria are met and informed consent from the parents (and when old enough, assent from the children) is obtained, children will be included in the trial. During the inclusion visit an open 20' cooked milk oral food challenge (OFC) needs to be passed in the hospital. Each visit a validated pedQuality of life (QoL) questionnaire will be taken and blood will be drawn to determine baseline specific IgE (sIgE) and IgG4 to cow's milk. Subjects (n=75) are randomized in a 1/1/1 ratio across three arms for 12 months to study the arm's tolerance inducing capacity (see Arms and Interventions for more information). After 6 months patients are invited for an intermediate visit. After 12 months, a OFC with unheated milk will be performed in all children during their challenge visits. Three months after the OFC, the children will be invited for a termination visit. Children who did not pass the OFC with unheated cow's milk after 12 months, will be invited to an observational 48 months follow-up study, in order to later-on retrieve the potential moment of complete cow's milk tolerance induction by clinical files.

WP2: Study of the immunological mechanisms (Treg and Breg induction and switch to IgG4-producing B cells).

Venous blood will be taken from all 75 children recruited for WP1 at enrolment and at the challenge and termination visit and from 15 healthy age-matched children, after obtaining children's oral or written assent (where appropriate) and parent's informed consent. Peripheral blood mononuclear cells (PBMCs) will be isolated and stimulated by cow's milk proteins as well as a positive control. Membrane markers associated with regulatory activity on T cells will be studied by flow cytometry (FC), as well as cytokine production in the supernatant by meso scale discovery. Furthermore, B cells will be studied after PBMC stimulation by FC. Cow's milk specific IgG4 and cytokine production will also be studied in this culture supernatant.

WP3: In vitro BATs to mimic the outcome of OFC.

In vitro Basophil activation tests (BATs) will be fine-tuned by preparing extracts for 20', 15', 10', 5' cooked and fresh cow's milk. Fine-tuning will include the comparison of new protein extract batches with the first batches, the absence of background basophil activation upon contact with the lowest dose of allergen extract and the comparison of basophil activation of healthy and of allergic children in different phases of cow's milk tolerance, who should show differences depending on the grade of tolerance. After fine-tuning, BATs will be performed as described above with 3 (or 5) extracts from cow's milk at baseline, challenge visit and termination visit in all children recruited within the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Food Allergy Cow Milk Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stepwise introduction using gradually shorter heating of cow's milk proteins

Step 1: open introduction of 20' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.

Step 2: open introduction of 15' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.

Step 3: open introduction of 10' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.

Step 4: open introduction of 5' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.

Group Type OTHER

Implementation of cow's milk in decreasingly heated forms

Intervention Type OTHER

Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

Stepwise introduction using the Flemish Milk Ladder

The first 5 steps of the Flemish Milk Ladder (each containing a, b and c part) will be gradually introduced at home, each step for 21 days (2-3X a week during 3 consecutive weeks after which 3 days "rest"). We consider the 6th step the equivalent of tolerance induction so step 6 will be allowed once the OFC with uncooked milk is passed.

Group Type OTHER

Implementation of cow's milk in decreasingly heated forms

Intervention Type OTHER

Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

Control arm with introduction of 20' cooked cow's milk

Step 1: open introduction of 20' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 12 months.

Group Type OTHER

Implementation of heated cow's milk

Intervention Type OTHER

Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

Healthy age-matched subjects

For work package 2, 15 healthy age-matched subjects are included to compare immunological mechanisms with.

Group Type OTHER

No intervention

Intervention Type OTHER

Healthy subjects undergo no intervention.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implementation of cow's milk in decreasingly heated forms

Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

Intervention Type OTHER

Implementation of heated cow's milk

Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

Intervention Type OTHER

No intervention

Healthy subjects undergo no intervention.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children (1-18y) had or have a clinical diagnosis of IgE mediated cow's milk allergy based on positive history as well as skin prick testing and/or specific IgE detection by CAPtest in an allergy clinic.
* Children are at least 12 months old before introduction of heated cow's milk is considered.
* Children did not suffer from grade 4 anaphylaxis due to cow's milk-ingestion at presentation.
* Children have specific IgE levels to Bos d 8 below 1.2 kU/mL and/or children passed 20' cooked cow's milk provocation test executed on clinical judgement.

Exclusion Criteria

* Children had grade 4 anaphylaxis due to cow's milk ingestion.
* Children are younger than 12 months old at the moment of passing 20' cooked cow's milk OFC.
* Parents are not able or not willing to adhere to a specific cow's milk protein-containing diet on a regular basis at home.
* Multiple food allergy, not compatible with any of the choices in the Flemish Milk Ladder.
* Parents and/or children are not willing to give IC/assent.
Minimum Eligible Age

1 Year

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dominque Bullens

Clinic Head in Pediatrics-Allergy at UZ Leuven, Head of the Allergy and Clinical Immunology Research group at KU Leuven (prof., dr.)

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jasmine Leus, MD

Role: PRINCIPAL_INVESTIGATOR

Maria Middelares Hospital, Gent

Katrien Coppens, MD

Role: PRINCIPAL_INVESTIGATOR

Imelda Hospital, Bonheiden

Sophie Verelst, MD

Role: PRINCIPAL_INVESTIGATOR

KU Leuven and Jessa Hospital, Hasselt

Kate Sauer, MD

Role: PRINCIPAL_INVESTIGATOR

AZ Sint-Jan AV

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Imelda Hospital Bonheiden

Bonheiden, , Belgium

Site Status RECRUITING

AZ Sint-Jan

Bruges, , Belgium

Site Status RECRUITING

AZ Maria Middelares

Ghent, , Belgium

Site Status RECRUITING

Jessa Hospital

Hasselt, , Belgium

Site Status RECRUITING

UZ Leuven Gasthuisberg

Leuven, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dominique MA Bullens, Prof. MD

Role: CONTACT

+32016343801

Marleen Jannis

Role: CONTACT

+32016343801

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Katrien Coppens, MD

Role: primary

Kate Sauer, MD

Role: primary

Jasmine Leus, MD

Role: primary

Sophie Verelst, MD

Role: primary

Dominique MA Bullens, Prof. Dr.

Role: primary

+32016343801

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

s68299

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

An Interventional Study of Milk Allergy
NCT00578656 COMPLETED EARLY_PHASE1
Milk Desensitization in Children
NCT03644381 UNKNOWN NA